论文部分内容阅读
目的:通过结核分枝杆菌初始耐药监测及耐药性趋势分析,更好地为临床结核病诊疗和防控策略调整提供科学依据。方法:采用L-J比例法对219例结核分枝杆菌进行抗结核药物异烟肼(INH,H)、利福平(RFP,R)、链霉素(SM,S)和乙胺丁醇(EMB,E)的耐药性检测,分析结核分枝杆菌耐药情况。结果:219株结核分枝杆菌经L-J比例法药物敏感检测,初始耐药率为20.5%,单耐药率为9.6%,耐多药率为5.9%;219株结核分枝杆菌对4种一线抗结核药物INH、RFP、SM和EMB的耐药率分别为13.2%、10.0%、6.8%和5.9%。结论:未经任何抗结核治疗的新发结核病例也存在耐药可能,加强耐药结核病的控制应根据实验室检测结果制定个体化治疗方案并坚持高质量的全程化疗。
OBJECTIVE: To provide a scientific basis for clinical diagnosis and treatment of tuberculosis and adjustment of prevention and control strategies through initial drug resistance surveillance and drug resistance trend analysis of Mycobacterium tuberculosis. Methods: 219 strains of Mycobacterium tuberculosis were treated with INH (H), Rifampicin (RFP, R), Streptomycin (SM, S) and ethambutol , E) drug resistance testing, analysis of Mycobacterium tuberculosis drug resistance. Results: 219 strains of Mycobacterium tuberculosis were sensitively tested by LJ method. The initial drug resistance rate was 20.5%, the single drug resistance rate was 9.6%, and the multidrug resistance rate was 5.9%. 219 strains of Mycobacterium tuberculosis were sensitive to 4 kinds of first-line The drug resistance rates of INH, RFP, SM and EMB were 13.2%, 10.0%, 6.8% and 5.9% respectively. CONCLUSIONS: New TB cases without any antituberculous therapy are also likely to have drug resistance. Strengthening the control of drug-resistant TB should be based on the laboratory test results to develop individualized treatment programs and adhere to high-quality full-course chemotherapy.